New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
Wei Cheng,Fen Li,Jing Tian,Xi Xie,Jin-Wei Chen,Xiao-Fei Peng,Qi Tang,Yan Ge
DOI: https://doi.org/10.2147/jir.s353539
IF: 4.5
2022-04-13
Journal of Inflammation Research
Abstract:Wei Cheng, Fen Li, Jing Tian, Xi Xie, Jin-Wei Chen, Xiao-Fei Peng, Qi Tang, Yan Ge Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China Correspondence: Yan Ge, Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China, Email Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments. Keywords: SAPHO, osteoarticular symptoms, cutaneous symptoms, immune pathway pathways, biologics, targeted small molecule compounds Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. There were no validated diagnostic criteria until 1988. 1 The presence of only 1 of the 4 inclusion criteria is sufficient to arrive at a diagnosis of SAPHO syndrome: (1) Osteo-articular manifestations of acne conglobata, acne fulminans, or hidradenitis suppurativa. (2) Osteo-articular manifestations of PPP.(3) Hyperostosis (of the anterior chest wall, limbs or spine) with or without dermatosis. (4) CRMO involving the axial or peripheral skeleton with or without dermatosis. In 1994, Kahn MF presented the diagnostic standards, which emphasized biopsy-proven aseptic osteitis limited clinical application. Therefore, it was revised again in 2003 as follows: 2 bone–joint involvement associated with isolated palmoplantar pustulosis (PPP); bone–joint involvement associated with severe acne; isolated or multifocal sterile hyperostosis/osteitis (adults); chronic recurrent multifocal osteomyelitis (children). Most related drugs come from case reports or single-center cohort studies because of the low incidence of SAPHO, and no consensus has been reached regarding the treatment of SAPHO syndrome. The treatment strategy is based on seronegative spondyloarthropathy. Non-steroid anti-inflammatory drugs (NSAIDs) are the first-line treatment in most patients; however, they are ineffective in some cases. Intra-articular injections or systemic oral glucocorticoids are effective in most patients. However, the chronic long-term adverse effects cannot be ignored, including relapse after dose reduction or withdrawal. Disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, sulfasalazine, cyclosporine A, cyclophosphamide, and thalidomide are used as second-line treatment; however, a significant percentage of patients fail to achieve remission. 3,4 After understanding the pathogenesis better, biologics were suggested for several cases refractory to conventional treatment and achieved good results. TNF blockers were the first choice; however, improvements in the cutaneous symptoms were unsatisfactory. For example, for patients unresponsive to TNF blockers, IL-1 inhibitors and biologics targeting the IL-17/IL-23 axis could be used. The latest case reports show JAK inhibitor therapy as a promising treatment strategy for SAPHO syndrome. This article reviews the application of biologics and other treatments based on the therapeutic targets and the size of molecules in SAPHO syndrome until September 2021 and summarizes the immune pathways involved in SAPHO syndrome pathogenesis and new drug treatments. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This might relate to the different inflammatory pathways involved in osteoarticular and cutaneous symptoms in SAPHO patients. Based on known pathogenesis, we provide stratified medication recommendations for SAPHO syndrome. Bone and skin damage should be evaluated first, followed by appropriate drug selection. The precise etiopathogenesis of SAPHO remains unclear; however, it is considered an autoinflammatory syndrome related to various etiologies, such as immune dysfunction, 4 infection, 5 and genetic sus -Abstract Truncated-
immunology